Shilajatvadi Vati and Bala Taila Matra Basti in the management of Mootraghata

Effect of Shilajatvadi Vati and Bala Taila Matra Basti in the management of Mootraghata w.s.r. to (Benign Prostatic Hyperplasia) An open labelled, randomized, comparative clinical trial.

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2019/02/017868

Enrollment

Registered

2019-02-28

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N401- Benign prostatic hyperplasia withlower urinary tract symptoms

Interventions

Intervention1: Group A: Shilajatvadi Vati will be given Orally 250 mg HS For 30 days to the patients(15) with Sahpan ajvayana and anupan milk Control Intervention1: Group B: Shilajatvadi Vat

Eligibility

Inclusion criteria

Inclusion criteria: Patients having signs and symptoms of Mootraghata(BPH) like Increase Frequency or Urgency Hesitancy Decrease Urine Flow Rate or Weak Stream Urine Retention(Acute and Chronic) Scanty micturition Painful micturition Dysuria(Burning micturition)

Exclusion criteria

Exclusion criteria: Age below 40 years Patients of malignancy congenital deformities of urogenital tract Any abdomino pelvic pathology other than BPH Systemic diseases like Uncontrolled Hypertension and diabetes mellitus Tuberculosis Paralysis Parkinsonism Known case of cardiac diseases etc will be excluded

Design outcomes

Primary

Measure	Time frame
Efficacy of Shilajatvadi Vati and Bala Taila Matra Basti in Benign Prostatic HyperplaciaTimepoint: 30 days	—

Secondary

Measure	Time frame
Safety of Shilajatvadi Vati and Bala Taila Matra Basti in Benign Prostatic HyperplaciaTimepoint: 30 days	—

Countries

India

Contacts

Public ContactDr Anup B Thakar

IPGT and RA Jamnagar

anup_thakar@yahoo.com9427776660

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026